Related Experiment Videos
Empiric therapy with amphotericin B in febrile granulocytopenic patients
T J Walsh1, J Lee, J Lecciones
1Section of Infectious Diseases, National Cancer Institute, Bethesda, Maryland 20892.
Abstract:
The early diagnosis of invasive fungal infection in granulocytopenic patients remains unreliable. Granulocytopenic patients who are persistently or recurrently febrile despite therapy with appropriate antibacterial agents are at high risk for the development of such infection. Two randomized clinical trials demonstrated that the empiric administration of amphotericin B to persistently or recurrently febrile granulocytopenic patients decreased the frequency, morbidity, and mortality of invasive fungal infection; these effects were especially marked in profoundly granulocytopenic patients who were not receiving antifungal prophylaxis. Current studies continue to indicate that prompt empiric administration of amphotericin B to persistently or recurrently febrile granulocytopenic patients ensures earlier treatment of deep mycoses. The roles of newer antifungal triazole compounds and of liposomal and lipid complexes of amphotericin B in empiric antifungal therapy must be investigated further in thoughtfully designed, randomized clinical trials.
Insights
Empiric amphotericin B reduces invasive fungal infections in febrile granulocytopenic patients. Prompt treatment with amphotericin B is crucial for managing deep mycoses in high-risk patients.
Area of Science:
- Mycology
- Hematology
- Infectious Diseases
Background:
- Early diagnosis of invasive fungal infections (IFIs) in granulocytopenic patients is challenging.
- Febrile granulocytopenic patients receiving antibacterial therapy are at high risk for IFIs.
- Profound granulocytopenia increases the risk of IFIs, especially without antifungal prophylaxis.
Purpose of the Study:
- To evaluate the efficacy of empiric amphotericin B in treating IFIs in febrile granulocytopenic patients.
- To assess the impact of empiric antifungal therapy on IFI-related morbidity and mortality.
- To highlight the need for further research into newer antifungal agents and formulations.
Main Methods:
- Review of two randomized clinical trials on empiric amphotericin B administration.
- Analysis of outcomes in persistently or recurrently febrile granulocytopenic patients.
- Comparison of outcomes with and without antifungal prophylaxis.
Main Results:
- Empiric amphotericin B significantly decreased the frequency, morbidity, and mortality of IFIs.
- The benefits were most pronounced in profoundly granulocytopenic patients without prophylaxis.
- Prompt empiric amphotericin B ensures earlier treatment of deep mycoses.
Conclusions:
- Empiric amphotericin B is effective in reducing IFIs in high-risk granulocytopenic patients.
- Further randomized trials are needed to investigate newer antifungal triazoles and amphotericin B lipid formulations.
- Optimizing empiric antifungal strategies remains critical for managing IFIs in immunocompromised patients.